These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30802411)

  • 21. Ibrutinib for mantle cell lymphoma.
    Tucker DL; Rule SA
    Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ibrutinib approved for the treatment of mantle cell lymphoma.
    Small S
    Clin Adv Hematol Oncol; 2013 Dec; 11(12):808. PubMed ID: 25016625
    [No Abstract]   [Full Text] [Related]  

  • 23. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.
    Bernard S; Goldwirt L; Amorim S; Brice P; Brière J; de Kerviler E; Mourah S; Sauvageon H; Thieblemont C
    Blood; 2015 Oct; 126(14):1695-8. PubMed ID: 26239089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is the open mouth mightier than the needle?
    Martin P
    Blood; 2015 Oct; 126(14):1638-9. PubMed ID: 26429964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.
    Gordon MJ; Raess PW; Young K; Spurgeon SEF; Danilov AV
    Br J Haematol; 2017 Nov; 179(3):501-503. PubMed ID: 27391978
    [No Abstract]   [Full Text] [Related]  

  • 26. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
    Bond DA; Alinari L; Maddocks K
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can we improve on ibrutinib in mantle cell lymphoma?
    Rule S
    Lancet Haematol; 2018 Mar; 5(3):e98-e99. PubMed ID: 29396093
    [No Abstract]   [Full Text] [Related]  

  • 28. Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma.
    Lee HJ; Chihara D; Wang M; Mouhayar E; Kim P
    Leuk Lymphoma; 2016 Dec; 57(12):2914-2916. PubMed ID: 27087288
    [No Abstract]   [Full Text] [Related]  

  • 29. Novel therapies for relapsed/refractory mantle cell lymphoma.
    Arora PC; Portell CA
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rare case of ocular adnexal relapse with mantle cell lymphoma treated with ibrutinib monotherapy.
    Nishiyama-Fujita Y; Nakazato T; Ito C; Ogura S; Mizuno K; Kamiya T; Aisa Y; Mori T
    Intern Med J; 2019 Sep; 49(9):1187-1189. PubMed ID: 31507052
    [No Abstract]   [Full Text] [Related]  

  • 31. Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.
    Vitagliano O; Trastulli F; Cacace F; Leone S; Memoli M; Scalia G; Notarangelo M; Mainolfi CG; De Renzo A; Pane F
    Leuk Lymphoma; 2018 Jul; 59(7):1734-1737. PubMed ID: 29019439
    [No Abstract]   [Full Text] [Related]  

  • 32. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
    Rule S; Dreyling M; Goy A; Hess G; Auer R; Kahl B; Cavazos N; Liu B; Yang S; Clow F; Goldberg JD; Beaupre D; Vermeulen J; Wildgust M; Wang M
    Br J Haematol; 2017 Nov; 179(3):430-438. PubMed ID: 28832957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.
    Landsburg DJ; Hughes ME; Koike A; Bond D; Maddocks KJ; Guo L; Winter AM; Hill BT; Ondrejka SL; Hsi ED; Nasta SD; Svoboda J; Schuster SJ; Bogusz AM
    Blood Adv; 2019 Jan; 3(2):132-135. PubMed ID: 30651281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ibrutinib therapy for lymphoplasmacytic lymphoma.
    Helber MJ; Moore JE; Williams AM; Meacham PJ; Rothberg PG; Zent CS
    Am J Hematol; 2017 Sep; 92(9):E542-E544. PubMed ID: 28543765
    [No Abstract]   [Full Text] [Related]  

  • 35. The Muddied Waters of Ibrutinib Therapy.
    Schamroth Pravda M; Schamroth Pravda N; Lishner M
    Acta Haematol; 2019; 141(4):209-213. PubMed ID: 30943468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
    Ma J; Lu P; Guo A; Cheng S; Zong H; Martin P; Coleman M; Wang YL
    Br J Haematol; 2014 Sep; 166(6):849-61. PubMed ID: 24957109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA grants accelerated approval for ibrutinib for CLL.
    Dangi-Garimella S
    Am J Manag Care; 2014 Mar; 20(5 Spec No.):E10. PubMed ID: 25618623
    [No Abstract]   [Full Text] [Related]  

  • 38. Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.
    Zhang L; Newberry KJ; Wang M
    Expert Rev Clin Immunol; 2013 Jun; 9(6):495-7. PubMed ID: 23730878
    [No Abstract]   [Full Text] [Related]  

  • 39. Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma.
    Furtado M; Wang ML; Munneke B; McGreivy J; Beaupre DM; Rule S
    Br J Haematol; 2015 Jul; 170(1):131-4. PubMed ID: 25559624
    [No Abstract]   [Full Text] [Related]  

  • 40. Ibrutinib-Associated Reversible Cardiomyopathy.
    Liang SH; Chiu CF; Bai LY
    J Oncol Pract; 2019 Dec; 15(12):671-673. PubMed ID: 31618089
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.